Search Results - "OCHS, Judith"

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 by GIACCONE, Giuseppe, HERBST, Roy S, GATZEMEIER, Ulrich, GROUS, John, OCHS, Judith S, AVERBUCH, Steven D, WOLF, Michael K, RENNIE, Pamela, FANDI, Abderrahim, JOHNSON, David H, MANEGOLD, Christian, SCAGLIOTTI, Giorgio, ROSELL, Rafael, MILLER, Vincent, NATALE, Ronald B, SCHILLER, Joan H, VON PAWEL, Joachim, PLUZANSKA, Anna

“…The purpose of this study was to determine whether the addition of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839;…”
Get full text

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 by HERBST, Roy S, GIACCONE, Giuseppe, WOLF, Michael K, KREBS, Annetta D, AVERBUCH, Steven D, OCHS, Judith S, GROUS, John, FANDI, Abderrahim, JOHNSON, David H, SCHILLER, Joan H, NATALE, Ronald B, MILLER, Vincent, MANEGOLD, Christian, SCAGLIOTTI, Giorgio, ROSELL, Rafael, OLIFF, Ira, REEVES, James A

“…Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase…”
Get full text

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials by BELL, Daphne W, LYNCH, Thomas J, KREBS, Annetta D, JOHNSON, David H, GIACCONE, Gmseppe, HERBST, Roy S, MANEGOLD, Christian, FUKUOKA, Masahiro, KRIS, Mark G, BASELGA, José, OCHS, Judith S, HABER, Daniel A, HASERLAT, Sara M, HARRIS, Patricia L, OKIMOTO, Ross A, BRANNIGAN, Brian W, SGROI, Dennis C, MUIR, Beth, RIEMENSCHNEIDER, Markus J, IACONA, Renee Bailey

“…Most cases of non-small-cell lung cancer (NSCLC) with dramatic responses to gefitinib have specific activating mutations in the epidermal growth factor…”
Get full text

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial by Kris, Mark G, Natale, Ronald B, Herbst, Roy S, Lynch, Jr, Thomas J, Prager, Diane, Belani, Chandra P, Schiller, Joan H, Kelly, Karen, Spiridonidis, Harris, Sandler, Alan, Albain, Kathy S, Cella, David, Wolf, Michael K, Averbuch, Steven D, Ochs, Judith J, Kay, Andrea C

“…CONTEXT More persons in the United States die from non–small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In…”
Get full text

Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma by REARDON, David A, QUINN, Jennifer A, PROVENZALE, James M, SAMPSON, John H, SMITH, Robert P, SWAISLAND, Alan J, OCHS, Judith S, LYONS, Peggy, TOURT-UHLIG, Sandy, BIGNER, Darell D, FRIEDMAN, Henry S, RICH, Jeremy N, VREDENBURGH, James J, GURURANGAN, Sridharan, FRIEDMAN, Allan H, DESJARDINS, Annick, SATHORNSUMETEE, Sith, HERNDON, James E, DOWELL, Jeannette M, MCLENDON, Roger E

“…Purpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal…”
Get full text

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial by HERBST, Roy S, MADDOX, Anne-Marie, OCHS, Judith, MUCCI LORUSSO, Patricia, ROTHENBERG, Mace L, SMALL, Eric J, RUBIN, Eric H, BASELGA, Jose, ROJO, Federico, WAUN KI HONG, SWAISLAND, Helen, AVERBUCH, Steven D

“…To investigate safety, tolerability, dose-related pharmacologic properties, and pharmacodynamics of ZD1839 (gefinitib, Iressa; AstraZeneca Pharmacueticals,…”
Get full text

Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors by Ochs, Judith S

“…The role of dysregulated epidermal growth factor receptor-tyrosine kinase (EGFR-TK) activity in promoting tumor resistance to radiation therapy is discussed,…”
Get more information

Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-Small-Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled Trial by CELLA, David, HERBST, Roy S, KRIS, Mark G, NATALE, Ronald B, LYNCH, Thomas J, PRAGER, Diane, BELANI, Chandra P, SCHILLER, Joan H, HEYES, Anne, OCHS, Judith S, WOLF, Michael K, KAY, Andrea C

“…PURPOSE Evaluation of disease-related symptom improvement rate by the Lung Cancer Subscale (LCS) of the Functional Assessment of Cancer Therapy-Lung (FACT-L)…”
Get full text

Pilot Trial of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib Plus Carboplatin and Paclitaxel in Patients With Stage IIIB or IV Non–Small-Cell Lung Cancer by MILLER, Vincent A, JOHNSON, David H, KRIS, Mark G, SMITH, Robert, OCHS, Judith, KRUG, Lee M, PIZZO, Barbara, TYSON, Leslie, PEREZ, Wendy, KROZELY, Peggy, SANDLER, Alan, CARBONE, David, HEELAN, Robert T

“…Gefitinib is an oral agent that inhibits the tyrosine kinase of the epidermal growth factor receptor. In phase I trials gefitinib was well tolerated and…”
Get full text

Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy by Giaccone, Giuseppe, Iacona, Renee B., Fandi, Abderrahim, Janas, Mette, Ochs, Judith S., Herbst, Roy S., Johnson, David H.

“…Purpose Two large, randomized, placebo-controlled trials (IRESSA NSCLC Trial Assessing Combination Therapy; INTACT 1 and 2) in non-small-cell lung cancer…”
Get full text

Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors by LORUSSO, Patricia M, HERBST, Roy S, BJORK, Thomas, MADDOX, Anne-Marie, ROTHENBERG, Mace L, SMALL, Eric J, RUBIN, Eric H, FEYEREISLOVA, Andrea, HEYES, Anne, AVERBUCH, Steven D, OCHS, Judith, BASELGA, José, RISCHIN, Danny, RANSON, Malcolm, CALVERT, Hilary, RAYMOND, Eric, KIEBACK, Dirk, KAYE, Stan, GIANNI, Luca, HARRIS, Adrian

“…Purpose: The feasibility and utility of assessing quality of life (QoL) and disease-related symptoms in patients with advanced cancer have been evaluated in…”
Get full text

Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis by Taylor, J S, Langston, J W, Reddick, W E, Kingsley, P B, Ogg, R J, Pui, M H, Kun, L E, Jenkins, 3rd, J J, Chen, G, Ochs, J J, Sanford, R A, Heideman, R L

“…Delayed cerebral necrosis (DN) is a significant risk for brain tumor patients treated with high-dose irradiation. Although differentiating DN from tumor…”
Get more information

Predominance of pilocytic histology in dorsally exophytic brain stem tumors by Khatib, Z A, Heideman, R L, Kovnar, E H, Langston, J A, Sanford, R A, Douglas, E C, Ochs, J, Jenkins, J J, Fairclough, D L, Greenwald, C

“…We report the magnetic resonance imaging (MRI) and clinico-histologic characterization of dorsally exophytic brain stem gliomas (DEBSGs). Between 1983 and…”
Get more information

Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital by Walter, A W, Hancock, M L, Pui, C H, Hudson, M M, Ochs, J S, Rivera, G K, Pratt, C B, Boyett, J M, Kun, L E

“…To evaluate the incidence of and potential risk factors for second malignant neoplasms of the brain following treatment for childhood acute lymphoblastic…”
Get more information

Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program by Govindan, Ramaswamy, Natale, Ronald, Wade, James, Herbst, Roy, Krebs, Annetta, Reiling, Richard, Hensing, Thomas, Wozniak, Antoinette, Belani, Chandra P., Kelly, Karen, Ochs, Judith

“…Chemotherapy (CT) is recommended in numerous clinical guidelines for advanced non-small cell lung cancer (NSCLC) and offers improved survival over best…”
Get full text

A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation by Mulhern, R K, Fairclough, D, Ochs, J

“…To compare the late neuropsychologic toxicities of CNS prophylaxis for childhood acute lymphoblastic leukemia (ALL), longitudinal assessments were performed on…”
Get more information

Bone Marrow Transplants from HLA-Identical Siblings as Compared with Chemotherapy for Children with Acute Lymphoblastic Leukemia in a Second Remission by Barrett, A. John, Horowitz, Mary M, Pollock, Brad H, Zhang, Mei-Jie, Bortin, Mortimer M, Buchanan, George R, Camitta, Bruce M, Ochs, Judith, Graham-Pole, John, Rowlings, Philip A, Rimm, Alfred A, Klein, John P, Shuster, Jonathan J, Sobocinski, Kathleen A, Gale, Robert Peter

“…Current regimens of intensive chemotherapy produce remissions in almost all children with acute lymphoblastic leukemia. Additional treatment with consolidation…”
Get full text

Predictors of Clinical Response of Non–Small Cell Cancer to Gefitinib by Ardizzoni, Andrea, Tiseo, Marcello

Get full text

Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study by Ochs, J, Mulhern, R, Fairclough, D, Parvey, L, Whitaker, J, Ch'ien, L, Mauer, A, Simone, J

“…We prospectively compared neuropsychologic functioning and clinical indicators of neurotoxicity in 49 consecutive childhood leukemia patients in long-term…”
Get more information

Phase I study of topotecan for pediatric patients with malignant solid tumors by Pratt, C B, Stewart, C, Santana, V M, Bowman, L, Furman, W, Ochs, J, Marina, N, Kuttesch, J F, Heideman, R, Sandlund, J T

“…To determine the dose-limiting toxicity and potential efficacy of topotecan in pediatric patients with refractory malignant solid tumors. In this phase I…”
Get more information